Log In
Print
BCIQ
Print
Print this Print this
 

Sonazoid, perflubutane (DD-723-B)

  Manage Alerts
Collapse Summary General Information
Company General Electric Co.
DescriptionIV perflubutane-based ultrasound contrast agent
Molecular Target
Mechanism of ActionDiagnostic; Imaging agent
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsContrast agent for ultrasound imaging of focal breast lesions; Contrast agent for ultrasound imaging of focal prostate lesions; Contrast for tumors
Regulatory Designation

Partner

Daiichi Sankyo Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today